NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates

NovoCure (NVCR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +46.01%. A quarter ago, it was expected that this oncology drug developer would post a loss of $0.42 per share when it actually produced a loss of $0.33, delivering a surprise of +21.43%.Over the last four quarters, the company ...